TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose
limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with
refractory or relapsed multiple myeloma (MM).